Join

Compare · PACB vs PKI

PACB vs PKI

Side-by-side comparison of Pacific Biosciences of California Inc. (PACB) and PerkinElmer Inc. (PKI): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both PACB and PKI operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
  • PKI is the larger of the two at $21.38B, about 43.0x PACB ($496.8M).
  • PACB has hit the wire 6 times in the past 4 weeks while PKI has been quiet.
  • PACB has more recent analyst coverage (24 ratings vs 17 for PKI).
MetricPACBPKI
Company
Pacific Biosciences of California Inc.
PerkinElmer Inc.
Price
$1.60+0.63%
$115.23-0.88%
Market cap
$496.8M
$21.38B
1M return
+19.40%
-
1Y return
+40.35%
-
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Laboratory Analytical Instruments
Exchange
NASDAQ
NYSE
IPO
2010
News (4w)
6
0
Recent ratings
24
17
PACB

Pacific Biosciences of California Inc.

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a collaboration with Invitae Corporation to develop ultra-high-throughput clinical whole genome sequencing platform; and a research collaboration with Rady Children's Institute for Genomic Medicine for whole genome sequencing platform. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PKI

PerkinElmer Inc.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Latest PACB

Latest PKI